Despite, limited data regarding the role of anti-BRAF-targeted therapies in spinal pilocytic astrocytomas, based on available data in their intracranial counterparts, there is a trend to consider anti-BRAF-targeted therapies as the treatment of choice in cases not amenable to resurgery. The gene discussed is BRAF; the disease is pilocytic astrocytoma.